title: Tolerance of mefloquine chemoprophylaxis in Dutch military personnel.
abstract: From June until October 1993, a battalion of Dutch marines was stationed in Cambodia for a United Nations deployment. In 73 volunteers who used mefloquine as malaria chemoprophylaxis, possible mefloquine-related adverse events were monitored with special emphasis on QT prolongation. All participants started mefloquine chemoprophylaxis with a loading dose (250 mg a day for three days) one week before departure, followed by a weekly dose (250 mg) for approximately 25 weeks. One month before (t - 1) and one (t + 1) and three (t + 3) months after mefloquine prophylaxis was started, an at rest electrocardiogram was made. Frequency, PR-, and QT-intervals were measured; blood samples for liver transaminases, total white blood cell count, and mefloquine concentration were obtained after one and three months. Adverse events such as dizziness, headache, coordination problems, and nausea were spontaneously reported in one (1.4%) and three (4.1%) persons at t + 1 and t + 3, respectively, while specific questioning revealed adverse events in nine (12.3%) and five (6.9%) persons, respectively, at the same time point. Three months after starting chemoprophylaxis, the heart rate at rest and total white blood cell count were lower (P < 0.05), while the QTc-interval was longer and levels of liver transaminases increased (P < 0.05), although both were still within the normal range. There was no extreme prolongation of the QTc-interval or increased levels of liver transaminases that resulted in a need to stop the chemoprophylaxis. No accumulation of mefloquine in the serum occurred, and no relationship was observed between the incidence of adverse events and serum mefloquine concentrations. The incidence of self reported mefloquine-related adverse events was low. In conclusion, mefloquine chemoprophylaxis was safe and well-tolerated in this group.
authors.affiliation: Department of Internal Medicine, University Hospital Utrecht, The Netherlands.
authors.forename: C A
authors.initials: CA
authors.lastname: Jaspers
authors.forename: A P
authors.initials: AP
authors.lastname: Hopperus Buma
authors.forename: P P
authors.initials: PP
authors.lastname: van Thiel
authors.forename: R A
authors.initials: RA
authors.lastname: van Hulst
authors.forename: P A
authors.initials: PA
authors.lastname: Kager
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D002160:Cambodia; D003967:Diarrhea / Q000139:chemically induced; D004244:Dizziness / Q000139:chemically induced; D004562:Electrocardiography / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D015767:Mefloquine / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D008875:Middle Aged; D008889:Military Personnel; D009426:Netherlands; D011597:Psychomotor Performance / Q000187:drug effects
chemical_list: D000962:Antimalarials; D015767:Mefloquine